Reuters logo
BRIEF-Amgen's Phase 3 A.R.R.O.W. study of once-weekly KYPROLIS regimen meets primary endpoint
October 23, 2017 / 8:08 PM / 2 months ago

BRIEF-Amgen's Phase 3 A.R.R.O.W. study of once-weekly KYPROLIS regimen meets primary endpoint

Oct 23 (Reuters) - Amgen Inc

* Phase 3 A.R.R.O.W. study of once-weekly KYPROLIS(carfilzomib) regimen meets primary endpoint of progression-free survival in relapsed and refractory multiple myeloma patients

* Amgen Inc - ‍overall safety profile of once-weekly KYPROLIS regimen was comparable to that of twice-weekly regimen​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below